Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials
An Open-label, Phase III Clinical Trial to Evaluate the Safety and Antiviral Activity of Clevudine in Chronic Hepatitis B Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials
Sponsor: Bukwang Pharmaceutical
Terminated
This trial was terminated. No reason was provided.
This PHASE3 trial investigates Hepatitis B and is currently terminated or withdrawn. Bukwang Pharmaceutical leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bukwang Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ami-dong, Seo-gu, South Korea , Amnam-dong, Seo-gu, South Korea , Anam-dong, Sungbuk-ku, South Korea , Banpo-dong, Seocho-gu, South Korea , Bupyoung-dong, Bupyoung-gu, South Korea , Daelim-dong, Yongdeungpo-gu, South Korea , Daemyoung-dong, Nam-gu, South Korea , Daesa-dong, Jung-gu, South Korea , Dogok-dong, Kangnam-gu, South Korea , Gaegeum-dong, South Korea and 20 more locations